Edith Cowan University

Research Online
Research outputs 2022 to 2026
3-1-2022

Assessing the causal effects of adipokines on uric acid and gout:
A two-sample mendelian randomization study
Ruyi Cong
Xiaoyu Zhang
Zihong Song
Shanshan Chen
Guanhua Liu

See next page for additional authors

Follow this and additional works at: https://ro.ecu.edu.au/ecuworks2022-2026
Part of the Diseases Commons
10.3390/nu14051091
Cong, R., Zhang, X., Song, Z., Chen, S., Liu, G., Liu, Y., ... & Xu, X. (2022). Assessing the Causal Effects of Adipokines
on Uric Acid and Gout: A Two-Sample Mendelian Randomization Study. Nutrients, 14(5), 1091. https://doi.org/
10.3390/nu14051091
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworks2022-2026/403

Authors
Ruyi Cong, Xiaoyu Zhang, Zihong Song, Shanshan Chen, Guanhua Liu, Yizhi Liu, Xiuyu Pang, Fang Dong,
Weijia Xing, Youxin Wang, and Xizhu Xu

This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworks2022-2026/403

nutrients
Article

Assessing the Causal Effects of Adipokines on Uric Acid and
Gout: A Two-Sample Mendelian Randomization Study
Ruyi Cong 1,† , Xiaoyu Zhang 2,3,† , Zihong Song 1 , Shanshan Chen 1 , Guanhua Liu 1 , Yizhi Liu 1 , Xiuyu Pang 1 ,
Fang Dong 1 , Weijia Xing 1 , Youxin Wang 3,4 and Xizhu Xu 1,5, *
1

2

3

4
5

*
†



Citation: Cong, R.; Zhang, X.; Song,
Z.; Chen, S.; Liu, G.; Liu, Y.; Pang, X.;
Dong, F.; Xing, W.; Wang, Y.; et al.
Assessing the Causal Effects of
Adipokines on Uric Acid and Gout:
A Two-Sample Mendelian
Randomization Study. Nutrients 2022,
14, 1091. https://doi.org/10.3390/

School of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences,
Tai’an 271000, China; rycong9832@163.com (R.C.); zhsong1996@163.com (Z.S.);
cshanshan2022@163.com (S.C.); liuguanhua200210@163.com (G.L.); yzliu20080910@163.com (Y.L.);
pangxy123@163.com (X.P.); fdong@sdfmu.edu.cn (F.D.); wjxing@sdfmu.edu.cn (W.X.)
Department of Anesthesiology, Sanbo Brain Hospital, Capital Medical University, Beijing 100093, China;
hydzxy@126.com
Beijing Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University,
Beijing 100069, China; wangy@ccmu.edu.cn
School of Medical and Health Sciences, Edith Cowan University, Perth 6027, Australia
The Second Affiliated Hospital of Shandong First Medical University, Tai’an 271000, China
Correspondence: xzxu@sdfmu.edu.cn; Tel.: +86-0538-623-1238
These authors contributed equally to this work.

Abstract: Previous observational studies have highlighted associations between adipokines and
hyperuricemia, as well as gout, but the causality and direction of these associations are not clear.
Therefore, we attempted to assess whether there are causal effects of specific adipokines (such as
adiponectin (ADP) and soluble leptin receptors (sOB-R)) on uric acid (UA) or gout in a two-sample
Mendelian randomization (MR) analysis, based on summary statistics from large genome-wide
association studies. The inverse-variance weighted (IVW) method was performed as the primary
analysis. Sensitivity analyses (including MR-Egger regression, weighted median, penalized weighted
median, and MR pleiotropy residual sum and outlier methods) were also performed, to ensure
reliable results. In the IVW models, no causal effect was found for sOB-R (odds ratios (OR), 1.002;
95% confidence intervals (CI), 0.999–1.004; p = 0.274) on UA, or ADP (OR, 1.198; 95% CI, 0.865–1.659;
p = 0.277) or sOB-R (OR, 0.988; 95% CI, 0.940–1.037; p = 0.616) on gout. The results were confirmed
in sensitivity analyses. There was no notable directional pleiotropy or heterogeneity. This study
suggests that these specific adipokines may not play causal roles in UA or gout development.
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1. Introduction
Uric acid (UA) is a waste product of purine catabolism. It can lead to gout when
this molecule nucleates in a joint or other tissue to form crystals of monosodium urate [1].
Gout is a chronic inflammatory disease that is influenced by genetic factors [2,3]. Gout
and hyperuricemia have become a major risk factor to human health, which are caused
by elevated UA [4]. Extensive evidence has shown that adipokines (such as adiponectin
(ADP) and soluble leptin receptors (sOB-R)) may be associated with changes in UA levels
and the development of gout [5–9]. Moreover, the causal relationship between ADP and
UA concentrations was demonstrated by a Mendelian randomization (MR) study with
Europeans [10].
Nevertheless, a large amount of inconsistent evidence was found in observational
studies, suggesting that confounders and reverse causality may be involved in the casual
effects of adipokines on UA and gout. The limitations of previous studies can be effectively
addressed by using MR [11]. MR method is a genetic epidemiological method, which can
assess causal inference by exploiting the genetic variants influencing a modifiable risk
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factor. According to Mendel’s genetic law, genetic material is randomly distributed during
meiosis and passed from parents to offspring at conception. Therefore, it is less susceptible
to residual confounding and reverse causality, and it makes causal inferences about the
effect of exposure on outcomes, using genetic variations closely related to the exposure
of interest as instrumental variables (IVs); which addresses the shortcomings of previous
observational epidemiology.
We conducted this study based on a two-sample MR framework, to explore the causal
effects of specific adipokines (i.e., ADP and sOB-R) on UA and gout.
2. Materials and Methods
This study is reported as per STROBE guidelines (Supplementary Table S1). In order
for causality to be valid in MR analysis, the following three hypotheses must be satisfied:
(a) The instruments of genetic variations must be robustly related to the concentration of
adipokines; (b) The genetic variations must not be associated with any confounder of the
adipokines and UA, as well as gout associations; And (c) the selected genetic variations
should not affect the UA or gout independently of its effect on adipokines [12].
2.1. Datasource and Selection of Instruments for MR
2.1.1. Outcome Datasource
Summary data for UA were obtained from a genome-wide association studies (GWAS)
of 42,741 European participants within the Global Urate Genetics Consortium (GUGC) [13].
For gout, a large sample of 69,374 participants (2115 cases and 67,259 controls) were
obtained from European populations within the GUGC [14]. We obtained these data
information for analysis from published GWASs on 20 February 2022 (https://gwas.mrcieu.
ac.uk/, accessed on 13 January 2022).
2.1.2. Selection of Instruments for MR
Summary data for adipokine variants were obtained from published GWAS (https://
gwas.mrcieu.ac.uk/, accessed on 8 September 2021) and publicly available GWAS databases
on 20 February 2022 [15,16] (Supplementary Table S2). In this study, genetic variants
were analyzed using MR, based on a significant genome-wide correlation with adipokine
concentrations (i.e., the inclusion criteria of p value at <5 × 10−8 ). All of the variants
were employed in linkage disequilibrium below 10%. Since this study only used publicly
available summary statistic from relevant GWAS and did not use the individual data,
ethical approval was not required.
For the causal effects of ADP (n = 39,883, individuals of mixed ethnicity (predominantly
European)) on UA or gout, we selected two sets of IVs using 23 and 25 variants. In addition,
rs2980879 and rs8060301 were removed, due to being palindromic with intermediate allele
frequencies.
Moreover, 4 variants locating in the LEPR gene were used to explain the causal effects
of sOB-R (n = 1000 individuals of European ancestry) on UA or gout. Information on all
single nucleotide polymorphisms (SNPs) as IVs involved in the MR analyses was provided
in the supplementary materials (Supplementary Table S3).
2.1.3. Statistics Power and F-Statistics
The power of this study was calculated using an online computing tool (https://shiny.
cnsgenomics.com/mRnd/, accessed on 13 January 2022). We fixed the type-I error rate
at 0.05 and the R2 of 0.05 for ADP and 0.001 for sOB-R, our study had sufficient power
(>80%) to detect the effects of adipokines on UA or gout [16]. Furthermore, based on the
approximation method, we calculated the mean F-statistic for each of the IVs selected [17].
2.2. Statistics Analysis
The standard inverse variance weighting (IVW) method assumed that each variant
contained was a valid IV, and this was a standard MR method for summary data [17]. We
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used the IVW method as the primary analysis. The random effects IVW model was used by
default, and the fixed effects model was used when the causal estimates between SNPs were
under-dispersion [18]. In addition, in order for causality to be valid in MR analysis, we also
performed a series of sensitivity analyses (such as weighted median, penalized weighted
median, leave-one-out method, MR pleiotropy residual sum and outlier (MR-PRESSO);
and MR-Egger regression) to test the robustness of the association.
Weighted median was used to account for the estimators, even though up to 50% of
the information was provided by invalid IVs [19]. Ineffective IV instruments affected the
median estimate, even if they did not directly contribute to the median estimate; therefore,
we also used penalized weighted median estimators [19]. In order to test the influence
of each SNP on the results, we adopted the leave-one-out method, which was based on
IVW point estimation after removing a SNP from the population [20]. The fluctuation of
the results before and after removal reflected the sensitivity of this SNP [20]. MR-PRESSO
consisted of three components (MR-PRESSO global test, MR-PRESSO outlier test, MRPRESSO distortion test) and relied on a regression framework with regressions based on
the effect of exposure on results provided by the slope of the regression line [21]. We also
used MR-PRESSO to evaluate the extent of horizontal pleiotropy.
MR-Egger regression was used to examine the influence of pleiotropy, assuming that
its strengths as an instrument did not affect the magnitude of the pleiotropic effects [17].
Estimates of the average pleiotropic effect of genetic variants included in the analysis could
be explained by the MR-Egger intercept [22]. To quantify the heterogeneity of the selected
variants, additionally, we assessed the Cochran’s Q statistic, which followed a distribution
with χ2 degrees of freedom equal to the number of SNPs minus one [23].
The MR results were presented as odds ratios (OR) with 95% confidence intervals (CI)
for each gene predicting increased risk factors. The link between exposure and outcome
with a p value < 0.05 was a considered significant statistical difference. Packages (such as
‘TwoSampleMR’ (version 0.5.6) and ‘MR-PRESSO’ (version 1.0)) in Rstudio (R version 4.1.2,
R Project for Statistical Computing) were used to perform MR analyses.
3. Results
As positive control, the causal effect of ADP on UA was confirmed in the IVW model
(OR per 1 mg/dL decreased in ADP concentration: 0.978; 95% CI, 0.961–0.996; p = 0.016), although invalid results were found for the weighted median (OR, 0.987; 95% CI, 0.961–1.013;
p = 0.324), penalized weighted median (OR, 0.987; 95% CI, 0.961–1.013; p = 0.311), and
MR-Egger (OR, 0.977; 95% CI, 0.939–1.016; p = 0.256) analyses (Table 1). The estimated
effect sizes of the SNPs on both the ADP and UA outcomes were displayed in a scatter plot
(Figure 1). Leave-one-out analysis showed that the elimination of any SNP did not cause
a change in the results (Supplementary Figure S1). Horizontal pleiotropy was not found
using the MR-PRESSO global test (p = 0.438). The MR-Egger analysis (intercept = 0.00007;
p = 0.946) also indicated that there was no notable directional pleiotropy. No heterogeneity
for the selected variants was found using Cochran’s Q statistic (p = 0.389). The F-statistics
of all 23 IVs were greater than 10 (Supplementary Table S3).
In the IVW model, ADP concentration was unrelated to risk of gout (OR, 1.198; 95%
CI, 0.865–1.659; p = 0.277), and similar invalid results were found for the weighted median
(OR, 1.043; 95% CI, 0.698–1.556; p = 0.839), penalized weighted median (OR, 1.025; 95% CI,
0.692–1.519; p = 0.901), and MR-Egger (OR, 1.024; 95% CI, 0.513–2.045; p = 0.947) analyses
(Table 1). The estimated effect sizes of the SNPs on both the ADP and gout outcomes
were displayed in a scatter plot (Figure 2). The leave-one-out analysis showed that the
elimination of any SNP did not cause a change in the results (Supplementary Figure S2).
No horizontal pleiotropy was found using the MR-PRESSO global test (p = 0.116). The
MR-Egger analysis (intercept = 0.024; p = 0.947) also indicated that there was no notable
directional pleiotropy. No heterogeneity for the selected variants was found by using
Cochran’s Q statistic (p = 0.083). The mean F-statistics were greater than 10 (Supplementary
Table S3).
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Table 1. Causal effects of ADP on UA and gout using MR analyses.
Phenotype

Numbers of SNPs

OR (95% CI)

Beta (SE)

p

Q Statistic

Nutrients
2022,
ADP vs.
UA14, x FOR PEER REVIEW

IVW
Weighted median
Penalised
globalweighted
test
median
MR-Egger
MR-PRESSO
egger_intercept
global test
ADP
vs. gout
MR-Egger
egger_intercept
IVW

Weighted
ADP
vs. goutmedian
Penalised
weighted
IVW
median
Weighted median
Penalised weighted
MR-PRESSO
median
global test
MR-PRESSO
MR-Egger
global test
egger_intercept
MR-Egger
egger_intercept

F-Statistic
4 of 11
4349.6

23
23

0.978 (0.961–0.996)
0.987 (0.961–1.013)

−0.022 (0.009)
−0.013 (0.014)

0.016
0.324

23

0.987 (0.961–1.013)

−0.013 (0.201)

0.438
0.311

23

0.977 (0.939–1.016)

23

−0.023 (0.020)
1.198 (0.865–1.659) 0.00007
0.181 (0.001)
(0.166)

0.146
0.946
0.438
0.256
0.946
0.277

1.043 (0.698–1.556)

0.042 (0.204)

0.839

25
25
25

1.198 (0.865–1.659)
1.025
(0.692–1.519)
1.043 (0.698–1.556)

0.181
0.025(0.166)
(0.201)
0.042 (0.204)

0.277
0.901
0.839

25
25

1.025 (0.692–1.519)

0.181(0.201)
(0.166)
0.025

0.288
0.901

23

25
25

25

−0.023 (0.020)
0.00007 (0.001)

−0.017 (0.011)

0.977 (0.939–1.016)

0.256
5751.4
0.083
5751.4
0.083

0.116

0.288
0.947
0.116
0.618
25
1.024 (0.513–2.045)
0.947
0.010
(0.019)
0.618
Beta is the estimated effect size. p < 0.05 was considered statistically significant. ADP: adiponectin;
CI:
confidence
intervals;
variables; statistically
IVW: inverse-variance
weighted;
MR: mendeBeta
is the estimated
effectIVs:
size.instrumental
p < 0.05 was considered
significant. ADP:
adiponectin;
CI: confidence
intervals; IVs: instrumental
variables;
IVW:residual
inverse-variance
MR:odds
mendelian
lian
randomization;
MR-PRESSO:
pleiotropy
sum andweighted;
outlier; OR:
ratio; randomization;
SE: standard
MR-PRESSO:
pleiotropy residual
sum and outlier; OR: odds ratio; SE: standard error; SNP: single-nucleotide
error;
SNP: single-nucleotide
polymorphism.

25

1.024 (0.513–2.045)

0.181 (0.166)

0.389

0.024 (0.353)
0.010(0.353)
(0.019)
0.024

polymorphism.

Figure 1.1. Scatter
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gout
forvariant.
each variant.
Error
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variance
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inverse-variance weighted; SNP: single nucleotide polymorphism.

In the IVW model, ADP concentration was unrelated to risk of gout (OR, 1.198; 95%
CI, 0.865–1.659; p = 0.277), and similar invalid results were found for the weighted median
(OR, 1.043; 95% CI, 0.698–1.556; p = 0.839), penalized weighted median (OR, 1.025; 95% CI,
0.692–1.519; p = 0.901), and MR-Egger (OR, 1.024; 95% CI, 0.513–2.045; p = 0.947) analyses
(Table 1). The estimated effect sizes of the SNPs on both the ADP and gout outcomes were
displayed in a scatter plot (Figure 2). The leave-one-out analysis showed that the elimina-
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analysis (intercept = 0.024; p = 0.947) also indicated that there was no notable directional
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pleiotropy. No heterogeneity for the selected variants was found by using Cochran’s
Q
statistic (p = 0.083). The mean F-statistics were greater than 10 (Supplementary Table S3).

Figure 2. Scatter plot showing the associations of the SNP effects on adiponectin, against the SNP
effects on gout. Circles indicate marginal genetic associations with adiponectin and risk of gout for
each variant.
variant. Error
bars indicate
indicate 95%
95% CIs.
CIs. MR:
MR: mendelian
mendelian randomization;
randomization; IVW:
IVW: inverse-variance
inverse-variance
each
Error bars
weighted;
SNP:
single
nucleotide
polymorphism.
weighted; SNP: single nucleotide polymorphism.

A causal effect of sOB-R on UA was not observed in our analysis. The invalid results
were found
foundfor
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model(OR,
(OR,
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weighted
mewere
1.002;
95%
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(OR,95%
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95% CI,
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(OR,
1.002;
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0.999–1.004;
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MR-Egger
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Table
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Numbers
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(95% CI) (OR, 0.985;
Beta (SE)
p
Q statistic
F-statistic
0.933–1.037;
= 0.544), and
95% CI, 0.901–1.078;
p = 0.779))
(Table 2).
sOB-R vs. UA
The scatter plot showed the results of MR analysis of each SNP using the IVW44.8
model
IVW
4 SNP removal
1.002was
(0.999–1.004)
0.274
0.961
(Figure 4).
found to not0.002
affect(0.001)
the results
in the leave-one-out
analysis
Weighted median
4
1.001
(0.999–1.004)
(0.002) was
0.326
(Supplementary
Figure
S4).
No horizontal0.001
pleiotropy
found using the MR-PRESSO
Penalised weighted median global test
4 (p = 0.697)1.001
(0.999–1.004)
0.001(0.002)
0.325 p = 0.959) for gout; and no
and MR-Egger
analysis
(intercept = 0.002;
heterogeneity
was found for the selected 0.002(0.0004)
variants using Cochran’s
Q statistic (p = 0.492).
MR-PRESSO
4
0.040
The F-statistics of all IVs were greater than 10 (Supplementary
global test
0.969Table S3).
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Table 2. Causal effects of sOB-R on UA and gout using MR analyses.
Phenotype

Numbers of SNPs

OR (95% CI)

Beta (SE)

p

Q Statistic

sOB-R vs. UA
IVW

44.8

Weighted
median
Nutrients
2022,
14, x FOR PEER REVIEW 4

1.002 (0.999–1.004)
1.001 (0.999–1.004)

0.002 (0.001)
0.001 (0.002)

0.274
0.326

4

1.001 (0.999–1.004)

0.001 (0.002)

0.325

0.002 (0.0004)

0.040

Penalised weighted
median
MR-PRESSO
global test
MR-Egger
MR-Egger
egger_intercept
egger_intercept

sOB-R vs. gout
sOB-R vs. gout
IVW
IVW
Weighted
median
Weighted median
Penalised weighted median
Penalised weighted
MR-PRESSO
median
global test
MR-PRESSO
global test
MR-Egger
MR-Egger
egger_intercept
egger_intercept

F-Statistic

4

4
4

4

4
4
4
4
4

4

6 of 11

0.002 (0.002) 0.969
0.578
0.002 (0.002)
0.578
0.00002(0.002) 0.991

1.002 (0.997–1.006)

1.002 (0.997–1.006)

0.00002 (0.002)

4
4
4
4

0.961

0.991

0.988 (0.940–1.037) −0.013 (0.025) 0.616
0.988 0.984
(0.940–1.037)
−0.013
(0.025)(0.027) 0.616
(0.933–1.037)
−0.016
0.547
0.984 (0.933–1.037)
−0.016 (0.027)
0.547
0.984 (0.933–1.037) −0.016 (0.027) 0.544
0.984 (0.933–1.037)
−0.016
(0.027)(0.022) 0.544
−0.013
0.615
0.697
−0.013 (0.022)
0.615
0.985 (0.901–1.078) −0.015 (0.046) 0.697
0.779
0.985 (0.901–1.078)
−0.0150.002
(0.046)
0.779
(0.028) 0.959

71.4
0.492

71.4

0.492

0.002 (0.028)
0.959
Beta is the estimated effect size. p <0.05 was considered statistically significant. sOB-R: soluble leptin
Beta
is the estimated
p < 0.05 wasintervals;
consideredIVs:
statistically
significant.
sOB-R:IVW:
soluble
leptin receptors;
receptors;
UA: uriceffect
acid;size.
CI: confidence
instrumental
variables;
inverse-variance
UA: uric acid; CI: confidence intervals; IVs: instrumental variables; IVW: inverse-variance weighted; MR:
weighted; MR: mendelian randomization; MR-PRESSO: pleiotropy residual sum and outlier; OR:
mendelian randomization; MR-PRESSO: pleiotropy residual sum and outlier; OR: odds ratio; SE: standard error;
oddssingle-nucleotide
ratio; SE: standard
error; SNP: single-nucleotide polymorphism.
SNP:
polymorphism.

Figure
Scatter plot
plot showing
showing the
the associations
associations of
of the
the SNP
SNP effects
effects on
on the
Figure 3.
3. Scatter
the sOB-R
sOB-R against
against the
the SNP
SNP
effects
on
the
uric
acid.
Circles
indicate
marginal
genetic
associations
with
sOB-R
and
risk
effects on the uric acid. Circles indicate marginal genetic associations with sOB-R and risk of
of uric
uric
acid for each variant.
variant. Error bars indicate 95% CIs. sOB-R: soluble leptin receptors; MR: mendelian
randomization; IVW: inverse-variance
inverse-variance weighted;
weighted; SNP:
SNP: single
single nucleotide
nucleotide polymorphism.
polymorphism.

No evidence of a causal effect of sOB-R on gout was found with either model (such
as the IVW model (OR, 0.988; 95% CI, 0.940–1.037; p = 0.616), weighted median (OR, 0.984;
95% CI, 0.933–1.037; p = 0.547), penalized weighted median (OR, 0.984; 95% CI, 0.933–
1.037; p = 0.544), and MR-Egger (OR, 0.985; 95% CI, 0.901–1.078; p = 0.779)) (Table 2). The
scatter plot showed the results of MR analysis of each SNP using the IVW model (Figure
4). SNP removal was found to not affect the results in the leave-one-out analysis (Supple-
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promoter of ADP [36]. The increase in PPAR γ mRNA induced by benzbromarone may
play a role in the mRNA expression of ADP in 3T3L1 cells [36]. Therefore, we speculate
that drug therapy may be an important factor in the elevation of ADP in patients with
gout. In addition, insulin resistance leads to increases in URAT1 and GLUT9 [29]. Under a
high purine load, insulin resistance can enhance UA reabsorption, which is manifested as
upregulation of URAT1 expression [37]. Similarly, elevated levels of URAT1 protein have
been observed in obesity/metabolic syndrome model mice [38]. In obese patients, ADP
is thought to be closely related to insulin resistance [7]. Overall, the correlation between
ADP and gout in observational studies may only be an accompanying relationship or
influenced by confounding factors, and ADP does not play a direct role in the occurrence
and development of gout.
As the main leptin receptor in circulating blood, sOB-R is closely related to leptin binding activity [39]. Numerous studies have shown that high levels of UA are accompanied by
high levels of serum leptin [40–43]. High concentrations of leptin were detected in both
severe gout patients and in the acute phase of gout [8,27]. Under the action of a feedback
regulation mechanism, the concentration of sOB-R in circulating blood may be influenced
by changes in leptin levels. A study suggested that the mRNA levels of leptin receptors
in peripheral blood mononuclear cells of patients with gout were significantly elevated,
usually binding to leptin and transducing downstream signals [8]. We also attempted to
investigate the causal effects of leptin on UA and gout, but there were not enough SNPs
as IVs to support MR analyses. Based on a two-sample MR framework and using a large
European population sample, we also found no evidence of a causal effect of sOB-R on UA
or gout.
Studies have shown that females have significantly higher leptin levels than males, possibly due to the testosterone effect in men, which inhibits leptin production in adipocytes [41–46].
Leptin concentrations were positively correlated with UA in premenopausal females and
elevated in females with hyperuricemia [47,48]. Therefore, the concentration of sOB-R, which
is closely related to leptin levels, may also differ between the sexes. Similarly, UA differs
between the sexes and is thought to be caused by estrogen [49,50]. This phenomenon suggests
that estrogen and the over-representation of females in the sample may have influenced these
results. However, these results may be related to the fact that gender-specific adipokines
data are not available. Therefore, the causal effects of adipokines on UA cannot be accurately described between the sexes. This limitation reflects the need for sex-stratified GWASs
and sex-specific research in this area of the causal effects of adipokines on UA and gout in
the future.
There are three main strengths of our MR analyses in the present study. First of all,
we used large-scale summary data sets of ADP, sOB-R, gout, and UA. Second, we found
no heterogeneity or pleiotropic of the IVs using multiple sensitivity analysis models and
Cochran’s Q statistic. Thus, despite the limited number of powerful genetic instruments,
the accuracy of the resulting MR estimates and the reliability of the results were significantly
improved. Third, our MR analyses more effectively avoided potential confounding factors
and reverse causality than traditional observational studies.
Without doubt, there were several limitations to our analyses. First, in terms of data,
we selected a mixed population sample of ADP, and the resulting racial differences should
not be ignored. Next, summary level data were used in MR analyses, so it was not possible
to stratify the analysis by covariates of interest. Finally, our samples were principally
European, which restricts the universality of our results to other ethnic groups.
5. Conclusions
In summary, in this two-sample MR study, our results do not support causal effects of
these specific adipokines on UA or gout. Our results suggest that these specific adipokines
do not play a causal role in UA or gout development.
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